| Code | CSB-RA004936MB22HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to YH-003, targeting CD40, a member of the tumor necrosis factor receptor superfamily. CD40 is a transmembrane protein expressed on antigen-presenting cells, B cells, and various non-immune cells, playing a crucial role in immune activation and regulation. Upon binding with its ligand CD40L, CD40 initiates signaling cascades that promote B cell proliferation, immunoglobulin class switching, and dendritic cell maturation. Dysregulation of CD40 signaling is implicated in autoimmune diseases, inflammatory conditions, and hematological malignancies, while its immunostimulatory properties make it an attractive target for cancer immunotherapy research.
YH-003 is an agonistic anti-CD40 antibody that has been investigated in clinical studies for its potential to enhance anti-tumor immunity. This biosimilar antibody serves as a valuable research tool for investigating CD40-mediated immune mechanisms, studying checkpoint modulation in oncology, exploring therapeutic strategies for B cell malignancies, and evaluating immune cell activation pathways in various disease models.
There are currently no reviews for this product.